Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 299 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Lesion Clear all
Active, not recruiting Not applicable Interventional Results available

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

NCT03070236
View directory record Official record
Conditions
Breast Cancer
Interventions
Survey
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
6
States / cities
Boston, Massachusetts • Newton, Massachusetts • Weymouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can We Miss Pigmented Lesions in Psoriasis Patients?

NCT01053819
View directory record Official record
Conditions
Psoriasis, Melanoma, Non-melanoma Skin Cancer
Interventions
etanercept
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 21, 2026, 10:52 PM EDT
Not listed No phase listed Observational

A Sample Collection Study Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits

NCT04668846
View directory record Official record
Conditions
Dermatologic Diseases
Interventions
non-invasive sample collection of skin tissue
Other
Lead sponsor
DermTech
Other
Eligibility
21 Years and older
Enrollment
1,000 participants
Timeline
2020 – 2023
U.S. locations
2
States / cities
Denver, Colorado • Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeated Insult Patch Test

NCT03474874
View directory record Official record
Conditions
Dermatitis, Allergy, Contact Allergy
Interventions
NeoMatriX Collagen Dressing
Device
Lead sponsor
NeXtGen Biologics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 21, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

NCT06085833
View directory record Official record
Conditions
Breast Cancer
Interventions
Nanomechanical Phenotype Test
Diagnostic Test
Lead sponsor
ARTIDIS AG
Industry
Eligibility
18 Years and older
Enrollment
2,706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
4
States / cities
Dallas, Texas • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 4 Interventional

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

NCT00029224
View directory record Official record
Conditions
Breast Cancer, Multiple Myeloma, Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
7
States / cities
Stockton, California • Kissimmee, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

NCT02059499
View directory record Official record
Conditions
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
Interventions
imiquimod, fluorouracil, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 21, 2026, 10:52 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

NCT07214272
View directory record Official record
Conditions
Skin Resurfacing
Interventions
Fraxel® FTX Laser System
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
21 Years to 60 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
La Jolla, California • Miami, Florida • Naperville, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 10:52 PM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

NCT00989313
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
17
States / cities
Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Not applicable Interventional Results available

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

NCT04547998
View directory record Official record
Conditions
Vitiligo
Interventions
Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Irvine, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

NCT01806597
View directory record Official record
Conditions
Moderate to Severe Palmoplantar Psoriasis
Interventions
secukinumab 150 mg, secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 21, 2026, 10:52 PM EDT
Completed No phase listed Observational Results available

Ultrasound Elastography of Breast Lesions

NCT00716482
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
SuperSonic Imagine
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Oct 21, 2026, 10:52 PM EDT
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
View directory record Official record
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

NCT04531813
View directory record Official record
Conditions
Hypersensitivity
Interventions
Butenafine HCl 1% (BAY1896425), Positive Control-Sodium lauryl sulfate (SLS), Negative Control
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 10:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions

NCT00633516
View directory record Official record
Conditions
Skin Cancer
Interventions
Optical Spectroscopy
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 21, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

NCT07213154
View directory record Official record
Conditions
Malignant Skin Neoplasm, Skin Disorder, Skin Neoplasm
Interventions
Quantitative Oblique Back-Illumination Microscopy, Radiation Therapy
Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 10:52 PM EDT
Completed No phase listed Observational

The Validation of New Photographic Technology for Assessing Skin Lesions

NCT06663241
View directory record Official record
Conditions
Skin Lesions
Interventions
Not listed
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

NCT01862900
View directory record Official record
Conditions
Metastatic Breast Cancer, Lung Metastases, Liver Metastases
Interventions
MEDI6469
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Not applicable Interventional Results available

Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery

NCT03202472
View directory record Official record
Conditions
Breast Neoplasm, Lesion
Interventions
Implanted Medical Device, Mammography, Questionnaire Administration, Radiofrequency (RFID) -Guided Localization, Ultrasonography
Device · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 21, 2026, 10:52 PM EDT
Recruiting Not applicable Interventional

Two-photon Fluorescence Microscopy of Dermatologic Biopsies

NCT07773688
View directory record Official record
Conditions
Basal Cell Carcinoma of Skin, Squamous Cell Carcinoma, Melanocytic Lesion, Adult
Interventions
Two photon microscopy imaging
Device
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Victor, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Not applicable Interventional

Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions

NCT02638935
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ultrasound- Virtual Touch Tissue Imaging Quantification
Device
Lead sponsor
Heidelberg University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

Diagnostic Effectiveness of Virtual Bronchoscopy

NCT00001515
View directory record Official record
Conditions
Bronchogenic Carcinoma, Chronic Granulomatous Disease, Job's Syndrome, Mycobacterium Infection, Wegener's Granulomatosis
Interventions
virtual bronchoscopy
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

NCT01672450
View directory record Official record
Conditions
Melanoma
Interventions
Intratumoral Ipilimumab and Interleukin-2
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 21, 2026, 10:52 PM EDT